Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas

Sambit K. Mohanty, Steven C. Smith, Elena Chang, Daniel J. Luthringer, Allen M. Gown, Manju Aron, Mahul Amin

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objectives: New immunohistochemical (IHC) markers of urothelial carcinoma (UCa) and prostatic adenocarcinoma (PCa) have emerged in recent years, yet comparative studies to establish markers remain lacking. We aimed to identify an effective but parsimonious approach for poorly differentiated bladder neck lesions, to establish a best practice panel approach in a setting simulating prospective use.

Methods: We tested the performance of a panel of IHC markers on whole sections of a consecutive cohort of transurethral resection specimens of poorly differentiated, challenging bladder neck resections (n = 36).

Results: In the setting of poorly differentiated bladder neck carcinomas, biomarker sensitivities for UCa were as follows: GATA3, 100%; S100P, 88%; p63, 75%; and cytokeratin (CK) 5/6, 56%; specificities of each were 100%. CK7 and CK20 showed sensitivities of 75% and 63%, though these were only 85% and 80% specific. For PCa markers, NKX3.1, p501S, prostate-specific membrane antigen, and androgen receptor (AR) each showed 100% sensitivity, outperforming ERG (35%) and prostate-specific antigen (PSA; 25%). All the prostate histogenesis markers were 100% specific, except for AR, which was positive in 13% of the UCa cases.

Conclusions: Novel IHC markers show improved diagnostic performance that enables positive and negative support for identifying histogenesis with the use of as few as two markers for this critical therapeutic distinction. PSA underperforms newer markers.

Original languageEnglish (US)
Pages (from-to)173-183
Number of pages11
JournalAmerican Journal of Clinical Pathology
Volume142
Issue number2
DOIs
StatePublished - Aug 1 2014
Externally publishedYes

Fingerprint

Prostate
Urinary Bladder
Biomarkers
Carcinoma
Androgen Receptors
Adenocarcinoma
Keratin-6
Keratin-5
Antigen Receptors
Prostate-Specific Antigen
Practice Guidelines
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. / Mohanty, Sambit K.; Smith, Steven C.; Chang, Elena; Luthringer, Daniel J.; Gown, Allen M.; Aron, Manju; Amin, Mahul.

In: American Journal of Clinical Pathology, Vol. 142, No. 2, 01.08.2014, p. 173-183.

Research output: Contribution to journalArticle

Mohanty, Sambit K. ; Smith, Steven C. ; Chang, Elena ; Luthringer, Daniel J. ; Gown, Allen M. ; Aron, Manju ; Amin, Mahul. / Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas. In: American Journal of Clinical Pathology. 2014 ; Vol. 142, No. 2. pp. 173-183.
@article{83168f5d907648dcac2dbd49aff14276,
title = "Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas",
abstract = "Objectives: New immunohistochemical (IHC) markers of urothelial carcinoma (UCa) and prostatic adenocarcinoma (PCa) have emerged in recent years, yet comparative studies to establish markers remain lacking. We aimed to identify an effective but parsimonious approach for poorly differentiated bladder neck lesions, to establish a best practice panel approach in a setting simulating prospective use.Methods: We tested the performance of a panel of IHC markers on whole sections of a consecutive cohort of transurethral resection specimens of poorly differentiated, challenging bladder neck resections (n = 36).Results: In the setting of poorly differentiated bladder neck carcinomas, biomarker sensitivities for UCa were as follows: GATA3, 100{\%}; S100P, 88{\%}; p63, 75{\%}; and cytokeratin (CK) 5/6, 56{\%}; specificities of each were 100{\%}. CK7 and CK20 showed sensitivities of 75{\%} and 63{\%}, though these were only 85{\%} and 80{\%} specific. For PCa markers, NKX3.1, p501S, prostate-specific membrane antigen, and androgen receptor (AR) each showed 100{\%} sensitivity, outperforming ERG (35{\%}) and prostate-specific antigen (PSA; 25{\%}). All the prostate histogenesis markers were 100{\%} specific, except for AR, which was positive in 13{\%} of the UCa cases.Conclusions: Novel IHC markers show improved diagnostic performance that enables positive and negative support for identifying histogenesis with the use of as few as two markers for this critical therapeutic distinction. PSA underperforms newer markers.",
author = "Mohanty, {Sambit K.} and Smith, {Steven C.} and Elena Chang and Luthringer, {Daniel J.} and Gown, {Allen M.} and Manju Aron and Mahul Amin",
year = "2014",
month = "8",
day = "1",
doi = "10.1309/AJCPK1OV6IMNPFGL",
language = "English (US)",
volume = "142",
pages = "173--183",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "2",

}

TY - JOUR

T1 - Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas

AU - Mohanty, Sambit K.

AU - Smith, Steven C.

AU - Chang, Elena

AU - Luthringer, Daniel J.

AU - Gown, Allen M.

AU - Aron, Manju

AU - Amin, Mahul

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Objectives: New immunohistochemical (IHC) markers of urothelial carcinoma (UCa) and prostatic adenocarcinoma (PCa) have emerged in recent years, yet comparative studies to establish markers remain lacking. We aimed to identify an effective but parsimonious approach for poorly differentiated bladder neck lesions, to establish a best practice panel approach in a setting simulating prospective use.Methods: We tested the performance of a panel of IHC markers on whole sections of a consecutive cohort of transurethral resection specimens of poorly differentiated, challenging bladder neck resections (n = 36).Results: In the setting of poorly differentiated bladder neck carcinomas, biomarker sensitivities for UCa were as follows: GATA3, 100%; S100P, 88%; p63, 75%; and cytokeratin (CK) 5/6, 56%; specificities of each were 100%. CK7 and CK20 showed sensitivities of 75% and 63%, though these were only 85% and 80% specific. For PCa markers, NKX3.1, p501S, prostate-specific membrane antigen, and androgen receptor (AR) each showed 100% sensitivity, outperforming ERG (35%) and prostate-specific antigen (PSA; 25%). All the prostate histogenesis markers were 100% specific, except for AR, which was positive in 13% of the UCa cases.Conclusions: Novel IHC markers show improved diagnostic performance that enables positive and negative support for identifying histogenesis with the use of as few as two markers for this critical therapeutic distinction. PSA underperforms newer markers.

AB - Objectives: New immunohistochemical (IHC) markers of urothelial carcinoma (UCa) and prostatic adenocarcinoma (PCa) have emerged in recent years, yet comparative studies to establish markers remain lacking. We aimed to identify an effective but parsimonious approach for poorly differentiated bladder neck lesions, to establish a best practice panel approach in a setting simulating prospective use.Methods: We tested the performance of a panel of IHC markers on whole sections of a consecutive cohort of transurethral resection specimens of poorly differentiated, challenging bladder neck resections (n = 36).Results: In the setting of poorly differentiated bladder neck carcinomas, biomarker sensitivities for UCa were as follows: GATA3, 100%; S100P, 88%; p63, 75%; and cytokeratin (CK) 5/6, 56%; specificities of each were 100%. CK7 and CK20 showed sensitivities of 75% and 63%, though these were only 85% and 80% specific. For PCa markers, NKX3.1, p501S, prostate-specific membrane antigen, and androgen receptor (AR) each showed 100% sensitivity, outperforming ERG (35%) and prostate-specific antigen (PSA; 25%). All the prostate histogenesis markers were 100% specific, except for AR, which was positive in 13% of the UCa cases.Conclusions: Novel IHC markers show improved diagnostic performance that enables positive and negative support for identifying histogenesis with the use of as few as two markers for this critical therapeutic distinction. PSA underperforms newer markers.

UR - http://www.scopus.com/inward/record.url?scp=84907224308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907224308&partnerID=8YFLogxK

U2 - 10.1309/AJCPK1OV6IMNPFGL

DO - 10.1309/AJCPK1OV6IMNPFGL

M3 - Article

VL - 142

SP - 173

EP - 183

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 2

ER -